ONCY logo

ONCOLYTICS BIOTECH INC

ONCYNASDAQ
🏆 #4316 by market capEarnings Oct 30US Equity
$831.45▲ $23.70 (+2.85%)
Simulated price
🔔
Track ONCY
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$67M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak
No chart data available for ONCY.

Trading Snapshot

Day Range
$821.90 – $845.15
52-Week Range
$0.64 – $1.51
Volume
$2.14B
Avg Volume
$2.72B
Shares Outstanding
100.4M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
-2.7
P/S Ratio
0.0x
EPS (TTM)
$-0.32
Dividend Yield
0.00%
Dilution (1yr)
+35.0%

Why Investors Own ONCY

  • ✓High-growth profile — revenue up +15.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ONCY logo

ONCOLYTICS BIOTECH INC

ONCY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$29M▲ +12.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +0.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
108.0M▲ +35.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▼ −$10M YoY
StockOtter · stockotter.space

About ONCOLYTICS BIOTECH INC

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$857.51
▲ +3.1% Upside
High Target$1,045.88
Low Target$785.69
Based on 12 analysts

Latest News & Updates

🚀
Barron’s·2h ago

ONCOLYTICS BIOTECH INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ONCY price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ONCOLYTICS BIOTECH INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.